Results 41 to 50 of about 9,857 (174)

Acetylcysteine increases sensitivity of ceftazidime-avibactam–resistant enterobacterales with different enzymatic resistance to ceftazidime-avibactam in vitro and in vivo

open access: yesBMC Microbiology, 2023
Abstract Background Ceftazidime-avibactam (CZA) improves treatment outcomes for infections caused by carbapenem-resistant organisms, but has led to serious bacterial resistance. Acetylcysteine (NAC) is an approved medication that protects the respiratory tract through antioxidant and anti ...
Zeyu Huang   +7 more
openaire   +3 more sources

Successful Rapid Desensitization to Ceftazidime/Avibactam in a Patient With Cystic Fibrosis and Multidrug-Resistant <i>Pseudomonas aeruginosa</i> Pneumonia: A Case Report. [PDF]

open access: yesClin Case Rep
ABSTRACT Ceftazidime/avibactam (CAZ‐AVI) is an important therapeutic option for multidrug‐resistant (MDR) Pseudomonas aeruginosa infections; however, hypersensitivity reactions may preclude its use and create significant therapeutic challenges. We report a 21‐year‐old woman with cystic fibrosis and recurrent MDR P.
Zhou Z   +6 more
europepmc   +2 more sources

Resistance to ceftazidime–avibactam and underlying mechanisms

open access: yesJournal of Global Antimicrobial Resistance, 2020
Ceftazidime-avibactam (CAZ-AVI) is a novel synthetic β-lactamase inhibitor combination. Although the combination has been available clinically for only a few years, cases of resistance to CAZ-AVI have already been reported.In the present review, we summarize the distribution of CAZ-AVI-resistant strains and the possible resistance mechanisms.There are ...
Yuhang Wang, Jin Wang, Rui Wang, Yun Cai
openaire   +3 more sources

In Vitro and In Vivo Evaluations of β-Lactam/β-Lactamase Mono- and Combined Therapies against Carbapenem-Nonsusceptible Enterobacteriaceae in Taiwan

open access: yesMicroorganisms, 2020
Increasing carbapenem resistance rates worldwide underscored the urgent need of novel antimicrobials. Ceftazidime–avibactam and aztreonam–avibactam combinations are developed to combat carbapenem resistance, but biological and geographic variations must ...
Tsung-Ying Yang   +10 more
doaj   +1 more source

Comparison of antimicrobial activity between ceftolozane–tazobactam and ceftazidime–avibactam against multidrug-resistant isolates of Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa

open access: yesInternational Journal of Infectious Diseases, 2017
Objective: This study compared the activity of ceftolozane–tazobactam and ceftazidime–avibactam against 120 bacterial strains, including extended-spectrum beta-lactamase (ESBL) producers, carbapenem-resistant Enterobacteriaceae (CRE), and Pseudomonas ...
Adnan Alatoom   +9 more
doaj   +1 more source

Clinical Experience with Ceftazidime-Avibactam for the Treatment of Infections due to Multidrug-Resistant Gram-Negative Bacteria Other than Carbapenem-Resistant Enterobacterales

open access: yesAntibiotics, 2020
Background: Experience in real clinical practice with ceftazidime-avibactam for the treatment of serious infections due to gram−negative bacteria (GNB) other than carbapenem-resistant Enterobacterales (CRE) is very limited.
Antonio Vena   +19 more
doaj   +1 more source

The Use and Effectiveness of Ceftazidime–Avibactam in Real-World Clinical Practice: EZTEAM Study

open access: yesInfectious Diseases and Therapy, 2023
Introduction Ceftazidime–avibactam has proven activity against multidrug-resistant (MDR) bacteria in clinical trials and real-world studies. This study was conducted to describe the patterns of use of ceftazidime–avibactam (including indications and ...
Alex Soriano   +22 more
doaj   +1 more source

Increased zinc levels facilitate phenotypic detection of ceftazidime-avibactam resistance in metallo-β-lactamase-producing Gram-negative bacteria

open access: yesFrontiers in Microbiology, 2022
Ceftazidime-avibactam is one of the last resort antimicrobial agents for the treatment of carbapenem-resistant, Gram-negative bacteria. Metallo-β-lactamase-producing bacteria are considered to be ceftazidime-avibactam resistant. Here, we evaluated a semi-
Michaela Simon   +16 more
doaj   +1 more source

Molecular mechanisms underlying bacterial resistance to ceftazidime/avibactam

open access: yesWIREs Mechanisms of Disease, 2022
AbstractCeftazidime/avibactam (CAZ/AVI), a combination of ceftazidime and a novel β‐lactamase inhibitor (avibactam) that has been approved by the U.S. Food and Drug Administration, the European Union, and the National Regulatory Administration in China. CAZ/AVI is used mainly to treat complicated urinary tract infections and complicated intra‐abdominal
Luying Xiong   +7 more
openaire   +2 more sources

Comparison of the

open access: yesJournal of Global Antimicrobial Resistance
Objectives: To provide a descriptive analysis of the in vitro antimicrobial susceptibility testing results for all 39,661 Pseudomonas aeruginosa isolates collected by the ATLAS global surveillance programme data from 2020 to 2024 with a focus on ...
Mark A. Estabrook   +3 more
doaj   +1 more source

Home - About - Disclaimer - Privacy